Compare OCS & CXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCS | CXII |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 597.4M |
| IPO Year | 2022 | 2026 |
| Metric | OCS | CXII |
|---|---|---|
| Price | $12.18 | $10.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $42.00 | N/A |
| AVG Volume (30 Days) | ★ 185.6K | 53.5K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $466.06 | N/A |
| Revenue Next Year | $479.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $10.05 |
| 52 Week High | $34.48 | $10.90 |
| Indicator | OCS | CXII |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 53.64 |
| Support Level | $10.63 | $10.59 |
| Resistance Level | $13.49 | $10.89 |
| Average True Range (ATR) | 0.44 | 0.10 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 12.28 | 25.00 |
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Churchill Capital Corp XII is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.